BiotechTube
Pharmatory

Pharmatory

Turku, Finland· Est.
pharmatory.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pharmatory is a private, Finland-based CDMO founded in 2015, with roots tracing back 25 years, offering end-to-end small molecule API development and manufacturing services under cGMP standards. The company serves a global clientele working on both new chemical entities (NCEs) and generic compounds, supported by an EMA/FIMEA-inspected facility. Recent growth is evidenced by a 2026 investment from MB Funds, positioning the company to expand its capabilities and customer partnerships in the evolving pharmaceutical outsourcing landscape.

Drug DeliverySmall Molecules

Technology Platform

Integrated small molecule API CDMO services, including route scouting, process R&D, scale-up, and cGMP manufacturing with a focus on complex chemistry and HPAPIs.

Opportunities

The growing trend of pharmaceutical outsourcing, especially for complex small molecules and HPAPIs, presents a significant opportunity.
Expansion in the veterinary pharma sector and supporting generic drug development post-patent expiry offer additional diversified growth avenues.

Risk Factors

Key risks include intense competition in the CDMO space, operational risks related to maintaining cGMP compliance and quality standards, and dependence on the health of the broader biopharma sector for client project flow and funding.

Competitive Landscape

Pharmatory competes in a crowded global CDMO market dominated by large players like Lonza, Catalent, and Cambrex, as well as many regional specialists. Its differentiation is based on a strong customer service culture, expertise in complex small molecule/HPAPI manufacturing, and a strategic European location with EMA certification.

More companies in Small Molecule Drugs →More companies in Finland →